about
Diagnosis and classification of Kawasaki diseaseA child with resistant Kawasaki disease successfully treated with anakinra: a case report.Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort studyNon-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment.Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.Incidence, epidemiology and clinical features of Kawasaki disease in Catalonia, Spain.Role of the Egami score to predict immunoglobulin resistance in Kawasaki disease among a Western Mediterranean population.Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.[Kawasaki disease is more prevalent in rural areas of Catalonia (Spain)].PReS-FINAL-2265: Tuberculosis in pediatric patients who are receiving anti-TNF agents.PReS-FINAL-1014: Role of MHC class I overexpression on muscle biopsy of patients with juvenile dermatomyositis.Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part oneInfecciones previas o coincidentes con la sospecha de enfermedad de Kawasaki ¿debemos cambiar nuestra actitud?Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group.[National consensus on the cardiological treatment and follow-up of Kawasaki disease]Canakinumab for the treatment of hyperimmunoglobulin D syndrome[National consensus on the cardiological treatment and follow-up of Kawasaki disease]
P50
Q22252396-5293A37F-E6A0-4288-9059-0D660A87243EQ36340938-CB5F40FA-A6D9-40A2-88E3-96A475BD2FB3Q36346686-1CBC3B38-0C05-43A4-A2E1-A3E30F0CE12DQ38155765-45FE414C-DE82-4670-B102-2774BB8C3B06Q38236298-CE3429A7-BE17-4AAE-91CE-C713A602C7E4Q39950397-AEA17DF7-3858-42E3-B98D-222A46E95D7CQ40740694-BC02EC82-98EA-45C3-93E3-3914A0F81CFAQ46974137-706C253F-8AA4-4B20-9DF8-ACB0EF517FACQ53478152-EEEA581F-639F-4DD0-9164-8A63316A667DQ55381620-83591D06-3FE3-40AF-A994-36428EB67E0BQ55542437-FDA9DCA7-24C8-45F0-A7C7-0E04D6E93E75Q56957893-A94BE863-46DF-44A9-ADC1-61E29226762DQ62005230-0EBD15D3-9336-49CB-A44B-A544EB194C22Q64993540-7355BCFE-3280-46B2-B176-CEE865287036Q88736737-2D784741-BDD2-4D81-8272-9FF1FB2A217FQ91086708-1835A2BF-5852-4AE4-9264-B75CD5FB286BQ91338059-2FEB8091-B8E5-42DD-A368-8FB9D580AE0D
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Judith Sánchez-Manubens
@ast
Judith Sánchez-Manubens
@en
Judith Sánchez-Manubens
@es
Judith Sánchez-Manubens
@nl
Judith Sánchez-Manubens
@sl
type
label
Judith Sánchez-Manubens
@ast
Judith Sánchez-Manubens
@en
Judith Sánchez-Manubens
@es
Judith Sánchez-Manubens
@nl
Judith Sánchez-Manubens
@sl
prefLabel
Judith Sánchez-Manubens
@ast
Judith Sánchez-Manubens
@en
Judith Sánchez-Manubens
@es
Judith Sánchez-Manubens
@nl
Judith Sánchez-Manubens
@sl
P108
P106
P108
P21
P31
P496
0000-0002-7615-4765